Top image

Press Release 2010

Heidelberg, 16 March 2010

The Nordic EMBL Partnership for Molecular Medicine officially inaugurates the Institute for Molecular Medicine Finland in Helsinki

The new Finnish Institute for Molecular Medicine (FIMM) is building a bridge from discovery to medicine

press16mar2010_s

The new Institute for Molecular Medicine Finland (FIMM) in Helsinki.
Image credit: FIMM.

 

Today, the Nordic EMBL Partnership for Molecular Medicine officially inaugurates the Institute for Molecular Medicine Finland (FIMM) in Helsinki. Together with the Centre for Molecular Medicine Norway (NCMM, University of Oslo) and the Laboratory for Molecular Infection Medicine Sweden (MIMS, Umeå University), FIMM is part of the Nordic EMBL Partnership for Molecular Medicine. The partnership was initiated in 2007 and is dedicated to research in molecular medicine, investigation of the molecular basis of disease and the discovery of new treatments.

“FIMM is a prime example of an international multi-disciplinary institute combining high-quality science with access to patient materials and links to medical expertise,” says Olli Kallioniemi, Director of FIMM. “Our state-of-the-art technologies enable us to investigate molecular mechanisms of disease using genomics and medical systems biology helping us to bridge from discovery to medical applications.”

The joint research institute is operated by the University of Helsinki, in collaboration with the Hospital District of Helsinki and Uusimaa (HUS), the National Institute for Health and Welfare (THL) and the VTT Technical Research Centre of Finland. FIMM has 150 employees in 11 research and five technology groups. The research groups work on cancer, cardiovascular, neuro-psychiatric and viral diseases. FIMM carries out translational research to explore new diagnostics and treatments and promotes human health via research on personalized medicine.

“EMBL is one of the most prominent institutes in molecular and cellular biology, while Finland and the University of Helsinki have strong expertise in clinical research. This provides an excellent base for building a world-class collaborative molecular medicine institute like FIMM,” says Iain Mattaj, Director General of EMBL.

FIMM will enhance its global profile by international recruitment, new career paths, and collaborations with industry and health care providers.

Press Contact

Sonia Furtado Neves
EMBL Press Officer, Meyerhofstraße 1, 69117 Heidelberg, Germany

Tel: +49 6221 387-8263
E-mail: sonia.furtado@embl.de

Policy regarding use

Press and Picture Releases

EMBL press and picture releases including photographs, graphics, movies and videos are copyrighted by EMBL. They may be freely reprinted and distributed for non-commercial use via print, broadcast and electronic media, provided that proper attribution to authors, photographers and designers is made.